-
Exports of medical devices grew sharply High-end medical device exports were weak
Time of Update: 2021-03-04
exports of medical devices grew at a On November 19, the official website of the State Council forwarded an article in the People's Daily, which pointed out that in the first 10 months, China's total value of foreign trade imports and exports reached 25.63 trillion yuan, an increase of 2.4% year-on-year, of which exports amounted to 13.99 trillion yuan, an increase of 4.9%.
-
Stone Pharmaceuticals' research and development investment increased by 64% in the first three quarters of the new drug sales revenue of 9.5 billion yuan
Time of Update: 2021-03-04
the first three quarters of 2019, Shi Pharmaceutical Group's pharmaceutical business maintained strong growth, with sales revenue of RMB13,387 million, up 35.1% YoY, according to the company's financial results.
-
The sale of a stake in Harmony Hospital by Fosun Pharma's subsidiary has been completed
Time of Update: 2021-03-04
After delivery, Fosun Pharma Holdings holding 9.4 million shares of NFC (approximately 7.04% of the total number of enlarged shares of NFC as of December 18, 2019) and no longer directly holding a limited partnership interest in HHH and a stake in Healthy Harmony GP.
-
Bo Ruikang a round of financing 60 million yuan to accelerate the "brain-machine interface" technology landing clinical
Time of Update: 2021-03-04
Huang Xiaoshan, general manager of Bo Ruikang, said that this round of financing funds is mainly used to accelerate the development of clinical products, to promote minimally invasion implanted feedback therapy and brain-computer intelligent active rehabilitation of products landing.
-
Howson landed in Hong Kong with 14 new products, which heavyweights will hit in 2019?
Time of Update: 2021-03-04
Table 4: Howson Pharmaceuticals is reviewing and reviewing the approval of the consistency evaluation application (MED China Drug Review Database 2.0) Howson Pharmaceuticals is currently in the review and approval of the injection consistency evaluation supplementary application involving 7 products, in addition to injection with Pometronate ii sodium has been evaluated enterprises, the remaining 6 products have the opportunity to become the first to be evaluated.
-
Aiji Taikang completed 50 million yuan B round of financing, Jinke Jun venture capital lead investment
Time of Update: 2021-03-04
Focusing on research and development innovations in high-volume sequencing target capture technology and the design and production of gene testing products, Aji taikang is a production service platform company driven by gene testing technology.
-
Baiji Shenzhou's latest response: The allegations in the short report are blatantly false
Time of Update: 2021-03-04
Capital Research, a capital research firm, released a report saying that Baiji state may have "faked" sales.
Notably, Baiji Shenzhou has not responded to seven questions in the short report of J.Capital Research, a capital research firm.
-
Innovative medicine blows! Hengrui's half-year revenue of 10 billion Chinese biopharmaceuticals 12.5 billion
Time of Update: 2021-03-04
In fact, as the largest pharmaceutical company by market capitalization in China, Hengrui Pharmaceuticals has also begun to shift its research and development focus to innovative pharmaceuticals, according to the semi-annual report, in the first half of 2019 Hengrui Pharmaceuticals invested 1,484 million yuan in research and development, an increase of 49.13 percent over the same period last year, and the proportion of research and development investment in sales revenue reached 14.80 percent.
-
Kantai Bio's first-half net profit fell 9.84% year-on-year to raise 3 billion yuan
Time of Update: 2021-03-04
According to Pacific Securities analysis, Kantai bio-research and development of the five seedlings are expected to be listed in 2021-2022; ( Sina Pharmaceutical News )
-
Kingsley and Seymru will work together in the life sciences and pharmaceuticals
Time of Update: 2021-03-04
August 19th, Kingsley Biotech (hereinafter: Kingsley) and Somerset Technologies (hereinafter referred to as Seymru) announced that they will jointly launch a comprehensive cooperation in the field of life sciences and biopharmaceuticals to jointly promote the development of the entire industrial chain of biopharmaceuticals from research and development to production.
-
6 provinces and regions set up a new free trade test zone, the development of the pharmaceutical industry focus!
Time of Update: 2021-03-04
On August 26, the State Council issued approval for the establishment of six new free trade pilot zones, agreeing to establish the China (Shandong) Free Trade Pilot Zone, the China (Jiangsu) Free Tr
-
The second batch of volume purchase lists flowed out of generic drugs to kill prices or more violently
Time of Update: 2021-03-04
From the industry spread "on the reporting and expansion of national organizations centralized procurement and use of drug varieties related procurement data notice", the current round of volume procurement involving a total of 35 drugs, a caposaccharide, metformin, albumin yew alcohol, tadalafa and other popular large varieties in the column.
-
Takeda Pharmaceuticals, the pharmaceutical industry's "snake swallowing elephant," will buy Shire for $58 billion
Time of Update: 2021-03-04
On December 5, local time, Takeda, the Japanese pharmaceutical group, announced the results of a shareholder meeting in which Takeda's shareholders approved the acquisition of Shire, the British maker of rare diseases.
-
Pre-loss of more than 2.2 billion yuan! People's fu medicine 3 billion goodwill "thunderstorm" landed at once
Time of Update: 2021-03-04
fu medicine has recently attracted market attention. First at the end of 2018 Fentanne "black swan" event, and then in January this year, the company's earnings forecast showed a sharp decline, the s
-
Where is the hard time for China's pharmaceutical industry in 2019 when old dividends are exhausted?
Time of Update: 2021-03-04
there are many signs that the pharmaceutical industry may really be harder than it's been before in 2020. It is not only a symbolic beginning of the new decade, is the old dividend to eat up the year
-
Pharmaceutical companies each make big moves to be shortlisted for the health insurance catalog
Time of Update: 2021-03-04
National opportunities brought about by the adjustment of the medical insurance catalogue As the largest payer of China's pharmaceutical market, the importance of drug release is self-evident, especially for the more expensive innovative drugs, included in the medical insurance catalog, on the one hand, can reduce the burden of patients, on the other hand, also increase the willingness of hospitals to use drugs.
-
Yinchuan City prescriptions all outflow, to solve the problem of licensing practicing pharmacists
Time of Update: 2021-03-04
Yinchuan City prescription audit and transfer platform access to 6 municipal hospitals, hospital prescriptions all outflow, in addition, Yinchuan City Health and Health Commission Director Ma Xiaofei made it clear that the platform solved the problem of licensing practicing pharmacists.
-
Medical imaging diagnostic equipment field: continuous improvement is worth looking forward to
Time of Update: 2021-03-04
Among them, the rapid development of domestic PET-CT/MRI, import substitution continued to improve, domestic magnetically controlled capsule gastroscope leading foreign enterprises approved for listing in China, in the medical examination and hospital market penetration has a greater room for improvement, domestic in-vascular ultrasound (IVUS) equipment has entered the special examination procedures for innovative medical devices, it is worth looking forward to.
-
The shortage of cheap drugs has eased this year
Time of Update: 2021-03-04
Recently, the supply of glyceal nitrate also caused the concern of Premier Li Keqiang of the State Council, admonished "to do a good job of commonly used drugs, first aid drugs to ensure stable prices, must not be out of stock, must not be wayetic price increases." The National Health and Safety Commission and other departments jointly issued a series of policies to address the shortage of drugs, targeted to solve the problem of drug supply.
-
China Resources Pharmaceutical Holdings indirectly holds a 30% stake in Jiang Traditional Chinese Medicine
Time of Update: 2021-03-04
20, Jiang Traditional Chinese Pharmaceuticals announced that China Resources Pharmaceuticals Holdings intends to take a 51% stake in Jiang zhong group and become its controlling shareholder. China Re
